12:00 AM
Jul 13, 2009
 |  BC Week In Review  |  Company News  |  Other News

Adherex cancer news

Adherex reshuffled its management and said it will focus its remaining resources on the development of eniluracil, after restructuring and reducing headcount in April. Adherex hired shareholder Rosty Raykov as CEO and a director to replace William Peters,...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >